Last updated: 2026-09-05 22:20:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Relay Therapeutics, Inc. (RLAY) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $19.06, with a market capitalisation of $4.17B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.86 to $21.27. This page covers its latest market performance, valuation, price trends and company information.
$4.17B | |
$18.85 | |
$64.37 | |
$1.78 | |
$19.01 | |
1.80M | |
3.05M | |
-- | |
$21.27 | |
$3.86 | |
-- | |
-- |
Relay Therapeutics, Inc. (RLAY) last closed at $19.01 as of 2026-09-04 23:31:00, unchanged from the previous close of $19.01.
During the latest regular trading session, RLAY traded between $1.78 and $64.37, with a volume of 1.80M shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Relay Therapeutics, Inc. (RLAY) moved from $19.42 to $19.06, representing a decline of 1.87% ($0.36).
The stock traded between $17.96 and $19.68 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 2.49 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 87.3%
RLAY is currently trading at $19.06, placing it 87.3% of the way from its 52-week low of $3.86 to its 52-week high of $21.27. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 192 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Relay Therapeutics, Inc. (RLAY) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.